Literature DB >> 6207208

Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation.

K Korttila, P Gröhn, A Gordin, S Sundberg, H Salo, E Nissinen, M A Mattila.   

Abstract

Six healthy male subjects were given in a crossover fashion medium molecular weight (HES 125) and low molecular weight (HES 40) hydroxyethyl starch, dextran, and balanced salt solution by intravenous infusion. The plasma volumes were determined using labeled albumin and plasma protein measurements. Three properties of factor VIII protein complex and indices of blood coagulation and hemostasis were measured before and after the infusions. Both the salt solution and HES 40 increased plasma volume, but their effect wore off within 3 hours. Dextran and HES 125 increased plasma volume significantly (P less than 0.001) more than the salt solution did, and the expansion was maintained for 24 hours. Plasma volume increases (dextran and HES 125) were associated with high nonglucose carbohydrate levels in plasma and low levels in urine. No or slight increases in plasma volumes (HES 40), on the other hand, were associated with low and high carbohydrate levels in plasma and urine, respectively. Serum alpha-amylase activity increased significantly after both HES preparations as compared to salt solution. Dextran and HES 125 decreased all the three values of factor VIII, these decreases being maximal 3 to 6 hours after administration and highest (about 25 per cent) for F VIII R:Ag and F VIII R:cof. It is concluded that HES 125 and dextran are equally effective plasma expanders.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207208     DOI: 10.1002/j.1552-4604.1984.tb01833.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

2.  Influence of different volume therapies on platelet function in the critically ill.

Authors:  J Boldt; M Müller; M Heesen; O Heyn; G Hempelmann
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

3.  Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation.

Authors:  K Waxman; R Holness; G Tominaga; P Chela; J Grimes
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

Review 4.  Colloid solutions for fluid resuscitation.

Authors:  Frances Bunn; Daksha Trivedi
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Hydroxyethylstarch as a risk factor for acute renal failure: is a change of clinical practice indicated?

Authors:  Joachim Boldt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Effect of 6% hydroxyethyl starch-450 and low molecular weight dextran on blood sugar levels during surgery under subarachnoid block: A prospective randomised study.

Authors:  Abhiruchi Patki; Vc Shelgaonkar
Journal:  Indian J Anaesth       Date:  2010-09

7.  A Comparative Coagulopathic Study for Treatment of Vasospasm by Using Low- and High-molecular Weight Hydroxyethyl Starches.

Authors:  Sung Ho Hwang; Yu Sam Won; Jang Sun Yu; Jae Young Yang; Chun Sik Choi
Journal:  J Korean Neurosurg Soc       Date:  2007-11-20

8.  [Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].

Authors:  H Kiesewetter; F Jung; J Blume; B Bulling; R P Franke
Journal:  Klin Wochenschr       Date:  1986-01-02

9.  Dextran administration avoids hemodynamic changes following paracentesis in cirrhotic patients. A safe and inexpensive option.

Authors:  R Terg; J Berreta; R Abecasis; G Romero; L Boerr
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

Review 10.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.